Sangamo Therapeutics, Inc.

Healthcare

NASDAQ:SGMO · NASDAQ Global Select

Market Cap $62.14M Beta 1.29 P/E (TTM) -0.5

$0.16 +4.53%

+$0.01 today

52W Low $0.10High $0.77

Vol 0.90M · Avg 9.89M

EPS (TTM)-$0.32

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

-68.07%

Period High

$0.74

Period Low

$0.10

Latest

$0.16

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

C4 Therapeutics, Inc.

NASDAQ:CCCC

$323.03M

Armata Pharmaceuticals, Inc.

AMEX:ARMP

$278.27M

OmniAb, Inc.

NASDAQ:OABI

$270.34M

Codexis, Inc.

NASDAQ:CDXS

$218.15M

Innate Pharma S.A.

NASDAQ:IPHA

$165.27M

Molecular Partners AG

NASDAQ:MOLN

$154.17M

Insight Molecular Diagnostics Inc.

NASDAQ:IMDX

$150.58M

Milestone Pharmaceuticals Inc.

NASDAQ:MIST

$109.08M

Invivyd, Inc.

NASDAQ:IVVD

$102.20M

Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

$49.65M

What is the latest SGMO filing?

The latest filing shown is 4 dated May 27, 2026.

How many recent filings does SGMO have?

Intrinsic Alpha currently shows 20 recent filings for SGMO.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.